Evidence map›Paper›PMID 42528143›Full record

ArticleThoracic cancer2026

ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.

Marion Caumeil, Julie A Vendrell, Simon Cabello-Aguilar, Sarah Cavaillon, Quentin Dominique Thomas, Jérôme Solassol

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marion CaumeilLaboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France.ORCID https://orcid.org/0009-0001-0792-7103
Julie A VendrellLaboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France.
Simon Cabello-AguilarLaboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0002-2904-7430
Sarah CavaillonInstitut du Cancer de Montpellier (ICM), Montpellier, France.ORCID https://orcid.org/0009-0006-1904-2130
Quentin Dominique ThomasInstitut du Cancer de Montpellier (ICM), Montpellier, France.
Jérôme SolassolLaboratoire de Biologie des Tumeurs Solides, CHU Montpellier, Université de Montpellier, Montpellier, France.ORCID https://orcid.org/0000-0002-0293-6158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor DNA (ctDNA) monitoring may detect resistance to KRAS

Indexed as

Carcinoma, Non-Small-Cell LungCirculating Tumor DNADrug Resistance, NeoplasmLung NeoplasmsProto-Oncogene Proteins p21(ras)AgedFemaleHumansMutationCirculating Tumor DNAKRAS protein, humanProto-Oncogene Proteins p21(ras)acquired resistanceadagrasibcirculating tumor DNAKRAS G12Cliquid biopsynon‐small cell lung cancer

Identifiers

PMID42528143
PMCPMC13420328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.